Cormorant Asset Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Cormorant Asset Management’s Portfolio RUBY Stock Details RUBY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-491,700	Closed	-$3.86M	–	83
2019 Q3	$3.86M	Sell	491,700 -108,300	-18%	-$1.26M	0.24%	60
2019 Q2	$9.44M	Sell	600,000 -50,000	-8%	-$807K	0.54%	51
2019 Q1	$11.8M	Buy	650,000 +289,090	+80%	+$4.44M	0.8%	39
2018 Q4	$5.8M	Sell	360,910 -3,649	-1%	-$66.5K	0.47%	44
2018 Q3	$8.75M	Buy	+364,559	New	+$8.34M	0.57%	38

Other funds holding RUBY

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Cormorant Asset Management's RUBY Position: Q4 2019 in Review

Cormorant Asset Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2019, closing a stake of 491,700 shares — an estimated $3.86M sold.

Cormorant Asset Management first reported a position in RUBY in Q3 2018 and held it in 5 quarters. The position peaked at $11.8M in Q1 2019. 76 funds tracked by Wall St. Rank hold RUBY as of Q4 2019.

Cormorant Asset Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
Cormorant Asset Management sold 491,700 Rubius Therapeutics, Inc shares in Q4 2019, an estimated $3.86M.
Cormorant Asset Management first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 5 quarters.
Cormorant Asset Management's Rubius Therapeutics, Inc position peaked at $11.8M in Q1 2019.
76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.